1. Home » 
  2. Quarterly Results » 
  3. Sanjivani Paranteral Q1 Results 27.78% QoQ Revenue Growth and 30.65% YoY Increase

Sanjivani Paranteral Q1 Results 27.78% QoQ Revenue Growth and 30.65% YoY Increase

Sanjivani Paranteral Q1 Results with total revenue of ₹16.44 crores, up 27.78% QoQ and 30.65% (YoY) and operating income increased by 14.78% QoQ and 23.67% YoY.   

by Ruksana

Updated Aug 30, 2024

Article continues below advertisement
Sanjivani Paranteral Q1 Results 27.78% QoQ Revenue Growth and 30.65% YoY Increase

Sanjivani Paranteral Quarterly Market Share Changes

Sanjivani Paranteral Q1 Results: In the first quarter of 2024, Sanjivani Parenteral reported strong financial results. Their total revenue reached ₹16.44 crores, which is a significant increase of 27.78% compared to the previous quarter and 30.65% higher than the same quarter last year. Their operating income, the money made from regular business activities, was ₹2.20 crores, showing a 14.78% improvement from the last quarter and a 23.67% increase year-over-year.

Sanjivani Paranteral’s expenses were mixed. Selling, general, and administrative expenses slightly decreased by 0.64% from the previous quarter but rose by 26.25% compared to last year. Depreciation and amortization costs, which are related to the wear and tear on equipment and intangible assets, dropped by 44.21% from the last quarter and by 42.06% from the same time last year. Other operating expenses, like costs for utilities and supplies, decreased by 41.29% from the previous quarter but were 12.05% lower compared to the previous year.

Sanjivani Paranteral’s net income, which is the company's profit after all expenses, was ₹1.71 crores. This was a 36.25% increase from the last quarter and a 10.58% rise from last year. The diluted normalized earnings per share (EPS), which shows how much profit is earned per share of stock, increased by 36.11% from the previous quarter but decreased by 5.16% from last year.

Here's a simplified summary of Sanjivani Parenteral's Q1 results:

Metric

Jun 24

Mar 23

QoQ Change

Jun 23

YoY Change

Total Revenue

16.44 cr

8.12 cr

+27.78%

12.58 cr

+30.65%

Selling/General/Admin Expenses

1.13 cr

1.33 cr

-0.64%

0.89 cr

+26.25%

Depreciation/Amortization

0.13 cr

0.23 cr

-44.21%

0.23 cr

-42.06%

Other Operating Expenses

2.71 cr

1.87 cr

-41.29%

3.09 cr

-12.05%

Total Operating Expense

14.23 cr

6.92 cr

+30.06%

10.80 cr

+31.80%

Operating Income

2.20 cr

1.20 cr

+14.78%

1.78 cr

+23.67%

Net Income Before Taxes

2.27 cr

1.00 cr

+20.68%

1.80 cr

+26.33%

Net Income

1.71 cr

1.00 cr

+36.25%

1.55 cr

+10.58%

Diluted Normalized EPS

1.47

1.00

+36.11%

1.55

-5.16%

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Article continues below advertisement
Article continues below advertisement

Sanjivani Paranteral Q1 Results 

The financial results for Sanjivani Paranteral for the quarter ended on June 30, 2024, show a positive performance compared to the previous year ended on March 31, 2024. For this quarter, the company’s total revenue was 1652.29 million rupees, up from 1291.66 million rupees in the previous year. This increase in revenue is mainly due to higher sales and other income.

Sanjivani Paranteral’s Expenses for the quarter were 1424.90 million rupees, which is higher than the previous year’s 1103.23 million rupees. The increase in expenses includes costs for materials, changes in inventory, and other operational costs. The company managed to control some costs like finance and depreciation expenses, which were lower compared to the previous year.

As a result, the profit of Sanjivani Paranteral before tax was 227.39 million rupees, an improvement from 188.43 million rupees last year. After accounting for taxes, which include current, previous, and deferred taxes, the net profit for the quarter was 171.39 million rupees, compared to 125.79 million rupees in the previous year.

Sanjivani Paranteral’s earnings per share also improved from 1.08 rupees to 1.47 rupees. Overall, the financial results show that Sanjivani Paranteral has increased its revenue and profit, reflecting a strong performance this quarter.

Here's a summary of the financial results:

Sr. No.

Particulars

Quarter Ended On 30-06-2024 (Unaudited)

Previous Year Ended On 31-03-2024 (Audited)

1

Revenue from Operations

   

a

Revenue from Operations

1643.72

1286.41

b

Other Income

8.57

5.25

Total Revenue

1652.29

1291.66

 

2

Expenses

   

a

Cost of Material Consumed

760.21

748.33

b

Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade

265.84

(253.29)

c

Employee Benefits Expenses

112.65

113.37

d

Finance Costs

1.59

8.84

e

Depreciation and Amortization Expenses

13.25

23.75

f

Other Expenses

271.36

462.23

Total Expenses

1424.90

1103.23

 

3

Profit/(Loss) Before Tax (1-2)

227.39

188.43

4

Tax Expenses

   

-

Current

56.00

56.77

-

Previous

0.00

1.06

-

Deferred

0.00

4.81

5

Net Profit/(Loss) for the Period (3-4)

171.39

125.79

6

Other Comprehensive Income (Net of Taxes)

0.00

0.00

7

Total Comprehensive Income for the Period

171.39

125.79

8

Comprehensive Income for the Period Attributable to the Owners of the Parent

171.39

125.79

9

Paid-up Equity Share Capital, (Face Value Rs.10/- Each)

1168.43

1168.43

10

Earnings Per Share (In Rs.)

   

a

Basic Earnings (Loss) Per Share

1.47

1.08

b

Diluted Earnings (Loss) Per Share

1.47

1.08

Article continues below advertisement
Article continues below advertisement

Sanjivani Paranteral Financial Performance

The table shows key financial details about Sanjivani Parenteral. The Market Cap is ₹369 Crores, indicating the total value of the company’s shares. The Current Price of one share is ₹316. The High / Low shows the highest price (₹316) and the lowest price (₹91.0) the stock has reached. The Stock P/E ratio of 58.2 reflects how expensive the stock is compared to its earnings. 

Sure! Here is the information in table format:

Metric

Value

Market Cap

₹369 Crores

Current Price

₹316

High / Low

₹316 / ₹91.0

Stock P/E

58.2

Book Value

₹23.9

Dividend Yield

0.00%

ROCE (Return on Capital Employed)

55.3%

ROE (Return on Equity)

49.7%

Face Value

₹10.0

Article continues below advertisement
Article continues below advertisement

Quarterly Results 

Sanjivani Parenteral table shows the company's financial results for three quarters: December 2023, March 2024, and June 2024. It details sales, which increased from ₹14.96 crores in December 2023 to ₹16.44 crores in June 2024. Expenses also grew, reaching ₹14.10 crores by June 2024. 

Here are the figures for December 2023, March 2024, and June 2024:

Particulars

Dec 2023

Mar 2024

Jun 2024

Sales (Rs. Crores)

14.96

12.86

16.44

Expenses (Rs. Crores)

12.99

10.70

14.10

Operating Profit (Rs. Crores)

1.97

2.16

2.34

OPM %

13.17%

16.80%

14.23%

Other Income (Rs. Crores)

0.25

0.05

0.09

Interest (Rs. Crores)

0.08

0.09

0.02

Depreciation (Rs. Crores)

0.24

0.24

0.13

Profit before Tax (Rs. Crores)

1.90

1.88

2.28

Tax %

13.16%

33.51%

24.56%

Net Profit (Rs. Crores)

1.65

1.26

1.71

EPS (Rs.)

1.65

1.08

1.46

About Sanjivani Paranteral 

Sanjivani Paranteral is a leading company in the pharmaceutical industry, dedicated to providing high-quality medicines to its customers. The company prides itself on its fast delivery services, ensuring that orders reach customers quickly and efficiently. They offer competitive prices, making their medicines affordable and accessible. Sanjivani Paranteral also focuses on a smooth supply chain process, which helps in maintaining quick and reliable service. 

Sanjivani Paranteral main goal is to meet and exceed the needs of their clients, whether the orders are large or small. They are flexible and can tailor their services to fit the specific needs of each customer. This means they can adjust their solutions based on the size and requirements of the order.

Sanjivani Paranteral puts a strong emphasis on customer satisfaction, making sure that their clients are happy with the products and services they receive. Their dedication to excellence and customer care is evident in everything they do, making them a trusted name in the pharmaceutical industry.


Sanjivani Paranteral Q1 Results - FAQs

1. What is the total revenue reported by Sanjivani Parenteral for Q1 2024?  

Sanjivani Parenteral reported a total revenue of ₹16.44 crores for Q1 2024.

2. How much did Sanjivani Parenteral’s operating income increase in Q1 2024?

Sanjivani Parenteral’s operating income increased by 14.78% in Q1 2024.

3. What is the net income of Sanjivani Parenteral for Q1 2024?

Sanjivani Parenteral’s net income for Q1 2024 is ₹1.71 crores.

4. What were Sanjivani Parenteral’s selling, general, and administrative expenses in Q1 2024?

Sanjivani Parenteral’s selling, general, and administrative expenses were ₹1.13 crores in Q1 2024.

5. By what percentage did Sanjivani Parenteral’s depreciation/amortization costs decrease in Q1 2024?

Sanjivani Parenteral’s depreciation/amortization costs decreased by 44.21% in Q1 2024.

6. What was the change in other operating expenses for Sanjivani Parenteral in Q1 2024?

Sanjivani Parenteral’s other operating expenses decreased by 41.29% in Q1 2024.

7. How much did Sanjivani Parenteral’s total expenses rise in Q1 2024?

Sanjivani Parenteral’s total expenses rose by 30.06% in Q1 2024.

8. What is Sanjivani Parenteral's market cap?

The Market Cap of Sanjivani Parenteral is ₹369 Crores.

9. How did Sanjivani Parenteral’s net profit before taxes change in Q1 2024?  

Sanjivani Parenteral’s net profit before taxes increased by 20.68% in Q1 2024.

10. What was the percentage change in Sanjivani Parenteral’s earnings per share from Q1 2023 to Q1 2024?  

Sanjivani Parenteral’s earnings per share decreased by 5.16% from Q1 2023 to Q1 2024.

Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.